^
Association details:
| Biomarker: | AR positive |
|---|---|
| Cancer: | Prostate Cancer |
| Drug: | Xtandi (enzalutamide) (Androgen receptor inhibitor) + zoligratinib (Debio 1347) (FGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Targeting the fibroblast growth factor pathway in molecular subtypes of castration-resistant prostate cancer
Published date:
10/05/2023
Excerpt:
In vivo studies using four ARPC PDX models showed that combination ENZA and CH5183284 significantly suppressed tumor growth.
DOI:
10.1002/pros.24630
